WARNING: “Buffett Indicator” flashing for first time in 50 years

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

James Chopas Biography and Net Worth

CAO of Apellis Pharmaceuticals

James G. Chopas CPA is the VP, Corp. Controller & Chief Accounting Officer at Apellis Pharmaceuticals Inc.

What is James George Chopas' net worth?: The estimated net worth of James George Chopas is at least $1.29 million as of March 15th, 2024. Mr. Chopas owns 38,883 shares of Apellis Pharmaceuticals stock worth more than $1,291,304 as of December 21st. This net worth approximation does not reflect any other investments that Mr. Chopas may own. Learn More about James George Chopas' net worth.
How old is James George Chopas?: Mr. Chopas is currently 57 years old. There are 8 older executives and no younger executives at Apellis Pharmaceuticals. Learn More on James George Chopas' age.
How do I contact James George Chopas?: The corporate mailing address for Mr. Chopas and other Apellis Pharmaceuticals executives is 100 FIFTH AVENUE, WALTHAM MA, 02451. Apellis Pharmaceuticals can also be reached via phone at (617) 977-5700 and via email at [email protected]. Learn More on James George Chopas' contact information.
Has James George Chopas been buying or selling shares of Apellis Pharmaceuticals?: James George Chopas has not been actively trading shares of Apellis Pharmaceuticals in the last ninety days. Most recently, James George Chopas sold 184 shares of the business's stock in a transaction on Friday, March 15th. The shares were sold at an average price of $56.46, for a transaction totalling $10,388.64. Following the completion of the sale, the chief accounting officer now directly owns 38,883 shares of the company's stock, valued at $2,195,334.18. Learn More on James George Chopas' trading history.
Who are Apellis Pharmaceuticals' active insiders?: Apellis Pharmaceuticals' insider roster includes Caroline Baumal (Insider), Victoria Brown (Insider), James Chopas (CAO), Mark DeLong (SVP), Pascal Deschatelets (Insider), A. Dunlop (Director), Jeffrey Eisele (Insider), Cedric Francois (CEO), Federico Grossi (Insider), Karen Lewis (Insider), Alec Machiels (Director), Nur Nicholson (Insider), Nicole Perry (VP), Lukas Scheibler (Insider), Timothy Sullivan (CFO), Adam Townsend (Insider), and David Watson (General Counsel). Learn More on Apellis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Apellis Pharmaceuticals?: During the last twelve months, insiders at the sold shares 30 times. They sold a total of 578,005 shares worth more than $32,477,597.17. The most recent insider tranaction occured on September, 16th when Director A. Sinclair Dunlop sold 37,000 shares worth more than $1,340,510.00. Insiders at Apellis Pharmaceuticals own 6.8% of the company. Learn More about insider trades at Apellis Pharmaceuticals.
Information on this page was last updated on 9/16/2024.

James George Chopas Insider Trading History at Apellis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/15/2024	Sell	184	$56.46	$10,388.64	38,883
1/22/2024	Sell	1,061	$65.00	$68,965.00	39,067
1/16/2024	Sell	864	$66.81	$57,723.84	40,128
10/23/2023	Sell	132	$46.04	$6,077.28	32,680
8/31/2023	Sell	551	$41.23	$22,717.73	30,312

James George Chopas Buying and Selling Activity at Apellis Pharmaceuticals

Apellis Pharmaceuticals Company Overview

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Today's Range

Now: $33.21

$32.89

$34.27

50 Day Range

MA: $30.31

$26.18

$35.42

2 Week Range

Now: $33.21

$24.34

$73.80

Volume

3,733,222 shs

Average Volume

2,007,418 shs

Market Capitalization

$4.13 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.94

WARNING: “Buffett Indicator” flashing for first time in 50 years

From Behind the Markets | Ad